Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 1

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1
Chunk 1
---
 which incorporate such “tissue building blocks” as collagen,
elastin, and proteoglycans such as heparin. Since these are naturally-occurring in the body, we believe they have an enhanced biocompatibility
with living tissues compared to synthetic biomaterials such as those based upon alpha-hydroxy polymers (e.g PLA, PLGA, and the like),
polyacrylamides, and other “natural” biomaterials that may lack the multiple proteins incorporated into our biomaterials.
These proprietary protein-based biomaterials that are similar to the body’s tissue thus allowing integration and tissue repair
in long-term implantation in certain applications.

Our
initial product, Spryng® is a veterinary medical device designed and engineered to provide a bio-integrative scaffold
in the affected joint, promoting restoration of proper joint mechanics. Spryng® is an intra-articular injectable product
of biocompatible and insoluble particles that are slippery, wet-permeable, durable, and resilient to enhance the force cushioning function
of the synovial fluid and cartilage. The particles mimic natural cartilage in composition, structure, and hydration. Multiple joints
can be treated simultaneously. Our particles are comprised of naturally derived collagen, elastin, and a glycosaminoglycan (i.e. heparin);
such particles mimic the composition and mechanical properties of extracellular matrix and natural cartilage. Spryng®
assists in promoting a constructive restoration of diseased synovial tissue to improve the biomechanics and mechanical homeostasis of
the joint. Furthermore, these particles are designed and engineered to provide a bio-integrative scaffold in the affected joint, promoting
restoration of proper joint mechanics.

Osteoarthritis,
a common inflammatory joint disease in both dogs and horses, is a chronic, progressive, degenerative joint disease that is caused by
a loss of synovial fluid and/or the deterioration of joint cartilage. Osteoarthritis affects approximately 14 million dogs and 1 million
horses in the $11 billion companion animal veterinary care and product sales market.

Despite
the market size, veterinary clinics and hospitals have very few treatments and/or drugs for use in treating osteoarthritis in dogs, horses,
and other pets. As there is no cure for osteoarthritis, current solutions treat symptoms, but do not manage the cause. The current treatment
for osteoarthritis in dogs generally consists of